388 related articles for article (PubMed ID: 30874878)
1. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
[TBL] [Abstract][Full Text] [Related]
2. Clinical Effectiveness of Preoperative 18F-FDG PET/CT in Predicting Pathological Tumor Grade in Patients with Pseudomyxoma Peritonei Originating from Appendix: A Retrospective Cohort Study.
Aso K; Gohda Y; Hotta M; Minamimoto R; Shimizu Y; Uemura Y; Yano H
Ann Surg Oncol; 2024 Mar; 31(3):1990-1995. PubMed ID: 38082170
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.
Dubreuil J; Giammarile F; Rousset P; Bakrin N; Passot G; Isaac S; Glehen O; Skanjeti A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1630-7. PubMed ID: 26907364
[TBL] [Abstract][Full Text] [Related]
4. Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction.
Passot G; Glehen O; Pellet O; Isaac S; Tychyj C; Mohamed F; Giammarile F; Gilly FN; Cotte E
Eur J Surg Oncol; 2010 Mar; 36(3):315-23. PubMed ID: 19818580
[TBL] [Abstract][Full Text] [Related]
5. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
[TBL] [Abstract][Full Text] [Related]
6.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
7. Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery.
Hotta M; Minamimoto R; Gohda Y; Tajima T; Kiyomatsu T; Yano H
Eur Radiol; 2020 Aug; 30(8):4193-4200. PubMed ID: 32211961
[TBL] [Abstract][Full Text] [Related]
8. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
9. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.
Yrjönen A; Koskenvuo L; Haapamäki C; Lepistö A
Scand J Surg; 2024 Jun; 113(2):140-149. PubMed ID: 37828760
[TBL] [Abstract][Full Text] [Related]
10. Optimal peritoneal cancer index cutoff point for predicting surgical resectability of pseudomyxoma peritonei in treatment-naive patients.
Bai M; Li Y; Pu H; Xu Y; Chen J; Xu H; Wei H; Liang G; Ma R; Feng J
World J Surg Oncol; 2024 Jan; 22(1):39. PubMed ID: 38297355
[TBL] [Abstract][Full Text] [Related]
11. Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei.
Han X; Zhang Q; Zhou N; Ma R; Wang J; Zhai X; Cui B; Lu Y; Liang L
Eur Radiol; 2023 Apr; 33(4):2800-2808. PubMed ID: 36418618
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of
Xian WJ; Feng YL; Wang Y; Yang M; Lu SN
Br J Radiol; 2022 Jan; 95(1129):20210279. PubMed ID: 34813375
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei.
Flood MP; Kong JC; Pham T; Waters PS; Soucisse M; Ramsay R; Wong HL; Mitchell C; Michael M; McCormick JJ; Warrier SK; Akhurst T; Heriot AG
Eur J Surg Oncol; 2022 Jul; 48(7):1606-1613. PubMed ID: 35148916
[TBL] [Abstract][Full Text] [Related]
14. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.
Zer A; Domachevsky L; Rapson Y; Nidam M; Flex D; Allen AM; Stemmer SM; Groshar D; Bernstine H
Eur Radiol; 2016 Sep; 26(9):3155-61. PubMed ID: 26685851
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of prognostic nomograms for pseudomyxoma peritonei patients after surgery: A population-based study.
Chen P; Su L; Yang W; Zhang J; Wang Y; Wang C; Yu Y; Yang L; Zhou Z
Medicine (Baltimore); 2020 Jul; 99(31):e20963. PubMed ID: 32756083
[TBL] [Abstract][Full Text] [Related]
17. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
18. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of
Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
